By Fineline Cube 
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received separate clinical approvals from the National Medical Products Administration (NMPA) for its Category 1 products HS-10510, HS-10542, and HS-20118. These approvals mark significant milestones in the company’s R&D pipeline, paving the way for further clinical development.
Clinical Studies to Commence
Hansoh Pharma will initiate clinical studies for each of these new drug candidates targeting various indications. HS-10510 will be studied for primary hypercholesterolemia and mixed dyslipidemia, addressing cardiovascular health needs. HS-10542 will focus on paroxysmal nocturnal hemoglobinuria, a rare blood disorder, while HS-20118 will target immunoglobulin A nephropathy and moderate to severe plaque psoriasis, expanding the company’s reach into nephrology and dermatology.
Expanding Therapeutic Footprint
These clinical approvals highlight Hansoh Pharmaceutical’s commitment to innovation and diversifying its therapeutic portfolio. By advancing these Category 1 products into clinical trials, Hansoh aims to address significant unmet medical needs across multiple disease areas, further solidifying its position as a leading biopharmaceutical company in China.-Fineline Info & Tech